Bausch Health wins Bryhali, Duobrii patent infringement case

Bausch Health announced that the US District Court for the District of New Jersey issued a favorable decision regarding Duobrii and Bryhali, in a suit filed against Padagis Israel Pharmaceuticals and Padagis. According to the ruling, the District Court found all the asserted patents valid and infringed. The current decision will serve to prevent approval of Padagis Bryhali and Duobrii generics until patent expiry in 2031 and 2036, respectively. Duobrii Lotion, 0.01%/0.045%, is a prescription medicine used on the skin to treat adults with plaque psoriasis. Bryhali Lotion, 0.01% is a prescription medicine used on the skin (topical) to treat adults with plaque psoriasis.